IL23A and psoriasis: Provided the interconnected nature of these signaling events, our findings underscore the therapeutic potential of targeting GzmK, not only as a means to modulate IL-23-driven inflammation, but also to regulate STAT3-driven keratinocyte proliferation through the PAR-1/MAPK pathway, offering a novel approach to psoriasis management.